Guan Maoying, Xu Weijie, Bai Haoran, Geng Zixiang, Yu Zhihua, Li Hegen, Liu Te
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
J Cancer. 2024 Jan 15;15(5):1314-1327. doi: 10.7150/jca.88038. eCollection 2024.
As a flavonoid compound, kaempferol has great potential in anti-lung cancer therapy, but the mechanism of its therapeutic effect needs further exploration. To explore the therapeutic effect of kaempferol on lung cancer, as well as its capability to regulate the gut microbiota and stimulate immune function. Materials & methods: Twenty-four BALB/c mice were divided into four groups. The first two groups, consisting of 12 normal mice, were administered either PBS or Kaempferol (Kaem) via gavage. The remaining 12 mice, which were subcutaneously inoculated with Lewis Lung Carcinoma (LLC) cells, were similarly divided and subjected to the same treatments respectively. The inhibitory effect of kaempferol on xenograft lung cancer models was explored with experiments, the diversity of gut microbiota was investigated by 16S rDNA sequencing, and the treatment effect on immune cells was quantified using flow cytometry. Kaempferol exerted a significant inhibitory effect on xenograft lung cancer models . It effectively inhibited the proliferation of LLC cells and significantly activated cytotoxic T cells, natural killer cells, and other immune cells in mice. 16S rRNA sequencing of fecal samples from tumor-bearing mice treated with kaempferol showed a significant increase in the abundances of potentially advantageous microbial species such as An increase in the proportions of three types of immune cells might associated with the above dominant bacterial species. Kaempferol can inhibit xenograft lung cancer models. Such inhibition effect might come from the activation of T cells, NK cells, and other immune cells which are modulated by the gut microbiota.
作为一种黄酮类化合物,山奈酚在抗肺癌治疗中具有巨大潜力,但其治疗效果的机制尚需进一步探索。为了探究山奈酚对肺癌的治疗效果及其调节肠道微生物群和刺激免疫功能的能力。材料与方法:将24只BALB/c小鼠分为四组。前两组各12只正常小鼠,分别通过灌胃给予磷酸盐缓冲液(PBS)或山奈酚(Kaem)。其余12只小鼠皮下接种Lewis肺癌(LLC)细胞,同样进行分组并分别接受相同处理。通过实验探究山奈酚对异种移植肺癌模型的抑制作用,采用16S rDNA测序研究肠道微生物群的多样性,使用流式细胞术定量分析对免疫细胞的治疗效果。山奈酚对异种移植肺癌模型具有显著抑制作用。它有效抑制了LLC细胞的增殖,并显著激活了小鼠体内的细胞毒性T细胞、自然杀伤细胞和其他免疫细胞。对用山奈酚治疗的荷瘤小鼠粪便样本进行16S rRNA测序,结果显示潜在优势微生物物种的丰度显著增加,如三种免疫细胞比例的增加可能与上述优势细菌物种有关。山奈酚可抑制异种移植肺癌模型。这种抑制作用可能源于由肠道微生物群调节的T细胞、NK细胞和其他免疫细胞的激活。